MNKD - MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation o
MNKD - MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF - Click For Release
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.